Study wrapper · #1164
Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.
Editor's note
The direction of this result runs against the common expectation that GLP-1 agonists worsen gut symptoms, which is what makes it worth a look. The absolute differences are small — roughly two to four percentage points — and the outcomes are diagnostic codes in health records, which capture what a clinician chose to document rather than what a patient actually experienced. Propensity matching cannot rule out that people prescribed these drugs differed in ways the data do not record, including care intensity. Regard it as a signal for a prospective study, not as evidence of benefit in IBS.
Plain-language abstract
Using the TriNetX network of electronic health records, researchers identified people newly diagnosed with irritable bowel syndrome who started a GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days of diagnosis, and matched them to similar IBS patients who did not. In the 90-day cohort of 6,665 patients per group, the GLP-1 group had modestly lower rates of coded chronic diarrhea (8.9% vs 10.6%), chronic constipation (19.8% vs 22.0%), abdominal pain (31.6% vs 35.8%), and bloating or distension (8.3% vs 10.9%). The pattern held in both diarrhea-predominant and constipation-predominant subtypes. Because this is a retrospective database analysis, it shows association only, and the authors describe it as hypothesis-generating.